Background: Arginase-1 and HepPar-1 are effective immunohistochemical (IHC) markers for hepatocellular carcinoma (HCC). In this study, we explored the possible efficacy of these stains in diagnosing pancreatic adenocarcinoma (PAD). Study Design: Arginase-1 and HepPar-1 IHC was performed on formalin-fixed, paraffin-embedded fine needle aspiration (FNA) cell blocks (CB) of PAD (n = 46), tissue microarray (TMA) of PAD (n = 33), FNA CB of HCC (n = 44) and TMA of HCC (n = 85). Negative controls without carcinoma were also applied (pancreas CB, n = 7; pancreas TMA, n = 3). Results: PAD CB demonstrated arginase-1 positivity in 0 of 46 cases and HepPar-1 positivity in 7 of 46 cases (15%). PAD TMA demonstrated arginase-1 positivity in 0 of 33 cases and HepPar-1 positivity in 4 of 33 cases (12%). HCC CB demonstrated arginase-1 positivity in 37 of 44 cases (84%) and HepPar-1 positivity in 32 of 44 cases (72%). HCC TMA demonstrated arginase-1 positivity in 75 of 85 cases (88%) and HepPar-1 positivity in 80 of 85 cases (94%). Conclusion: Both arginase-1 and HepPar-1 are effective IHC markers of hepatocellular differentiation. Arginase-1 demonstrates superior sensitivity and specificity compared with HepPar-1 in the diagnosis of HCC. However, both arginase-1 and HepPar-1 have a low sensitivity and a very high specificity for PAD.

Keywords:
Arginase-1, HepPar-1, Pancreatic adenocarcinoma, Hepatocellular carcinoma
1.
Taub R: Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004;5:836-847.
2.
Shinozuka H, Lombardi B, Sell S, et al: Early histological and functional alterations of ethionine liver carcinogenesis in rats fed a choline-deficient diet. Cancer Res 1978;38:1092-1098.
3.
Sirica AE: Ductular hepatocytes. Histol Histopathol 1995;10:433-456.
4.
Sirica AE, Mathis GA, Sano N, Elmore LW: Isolation, culture, and transplantation of intrahepatic biliary epithelial cells and oval cells. Pathobiology 1990;58:44-64.
5.
Bisgaard HC, Thorgeirsson SS: Evidence for a common cell of origin for primitive epithelial cells isolated from rat liver and pancreas. J Cell Physiol 1991;147:333-343.
6.
Duncan AW, Dorrell C, Grompe M: Stem cells and liver regeneration. Gastroenterology 2009;137:466-481.
7.
Grompe M: Pancreatic-hepatic switches in vivo. Mech Dev 2003;120:99-106.
8.
Fujiwara M, Kwok S, Yano H, Pai RK: Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine needle aspiration biopsies. Cancer Cytopathol 2012;120:230-237.
9.
Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM: Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977;4:53-58.
10.
Varadhachary GR, Abbruzzese JR, Lenzi R: Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776-1785.
11.
Hillen HFP: Unknown primary tumours. Postgrad Med J 2000;76:690-693.
12.
Wee A: Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology 2011;22:287-305.
13.
Linda DF: Benign and malignant tumors of the liver; in Robert DO, Goldblum JR (eds): Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas, ed 2. Philadelphia, Saunders, 2009, pp 1291-1325.
14.
Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
15.
Hammar SP: Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 1998;29:1393-1402.
16.
Brown RW, Campagna LB, Dunn JK, Cagle PT: Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: a diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997;107:12-19.
17.
Kakar S, Gown AM, Goodman ZD, Ferrell LD: Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 2007;131:1648-1654.
18.
Fan Z, van de Rijn M, Montgomery K, Rouse RV: Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003;16:137-144.
19.
Kakar S, Muir T, Murphy LM, Lloyd RV, Burgart LJ: Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol 2003;119:361-366.
20.
Kandil DH, Cooper K: Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol 2009;16:125-129.
21.
Shafizadeh N, Ferrell LD, Kakar S: Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008;21:1011-1018.
22.
Aviel-Ronen S, Lau SK, Pintilie M, et al: Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008;21:817-825.
23.
Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ: Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol 2006;30:1570-1575.
24.
Hishinuma M, Ohashi KI, Yamauchi N, et al: Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma. Histopathology 2006;49:479-486.
25.
Yan BC, Gong C, Song J, et al: Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 2010;34:1147-1154.
26.
Choi S, Park C, Ahn M, Lee JH, Shin T: Immunohistochemical study of arginase 1 and 2 in various tissues of rats. Acta Histochem 2012;114:713-718.
27.
McKnight R, Nassar A, Cohen C, Siddiqui MT: Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology. Cancer Cytopathol 2012;120:223-229.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.